Company profile
Verrica Pharmaceuticals Inc.
NASDAQ: VRCA · Healthcare · Biotechnology
#482 of 1,422 Healthcare companies by revenuetop-decile growth
EA Score
51DFH 53DQ 40GM 67SS 53
v0.1 · 65/100 weight · provisional
↑ revenue growth (YoY), 3-yr revenue growth · ↓ growth stability, disclosure history
Methodology →Revenue TTM
$37.2M
Rev growth YoY (TTM)
+417.6%
Net income (FY)
-$17.9M
Employees
76
as of 2026-08-19
Market cap
$80.4M
as of 2026-08-19
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$35.6M$35.6M2025
Net income-$17.9M-$17.9M2025
Operating income-$12.2M-$12.2M2025
Total assets$47.1M$47.1M2025
Liabilities$22.4M$22.4M2025
Equity$24.7M$24.7M2025
Revenue trend
FY2021 – FY2025 · USD
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
License And Collaboration Revenue57%
Product43%
By geography
Not disclosed.
The read
What is Verrica Pharmaceuticals Inc.’s revenue?
Verrica Pharmaceuticals Inc. booked $35.6M in FY2025 revenue, growing 370% year over year — faster than 93% of Healthcare companies we track, at a -50.3% net margin.
Peers · Healthcare
Sunshine Biopharma, Inc.50DC4 Therapeutics, Inc.49DEarth Science Tech, Inc.69BLeef Brands Inc.57CSenseonics Holdings, Inc.57CX4 Pharmaceuticals, Inc.51DNeighbors
Chester →Key facts
CEOJayson Rieger
SectorHealthcare
IndustryBiotechnology
HeadquartersWest Chester, PA
ExchangeNASDAQ: VRCA
Employees76
IPO date2018-06-15
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.